In another clinical study, rhIL-37 significantly downregulated the expression of TNF-α, IL-17, and IL-6 in PBMCs obtained from RA patients, whereas anti-TNF-α therapy significantly decreased the serum levels of IL-3736. This evidence concerns the gene IL17A and rheumatoid arthritis.